Actionable molecular alteration in cholangiocarcinoma — FGFR2 fusion / rearrangement, IDH...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-CHOLANGIOCARCINOMA-HIGH-RISK-BIOLOGY |
|---|---|
| Type | Red flag |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | DIS-CHOLANGIOCARCINOMA |
| Sources | SRC-NCCN-HCC-2025 SRC-ONCOKB |
Red Flag Origin
| Definition | Actionable molecular alteration in cholangiocarcinoma — FGFR2 fusion / rearrangement, IDH1 R132 mutation, BRAF V600E, HER2 amplification, NTRK fusion, MSI-high / dMMR, or BRCA1/2 mutation — opens a targeted-therapy line distinct from gem-cis-durvalumab and is decisive at progression. |
|---|---|
| Clinical direction | intensify |
| Category | high-risk-biology |
Trigger Logic
{
"any_of": [
{
"finding": "BIO-FGFR2-FUSION",
"value": "positive"
},
{
"finding": "BIO-IDH1-MUTATION",
"value": "positive"
},
{
"finding": "BIO-BRAF-V600E",
"value": "positive"
},
{
"finding": "BIO-HER2-SOLID",
"value": "positive"
},
{
"finding": "BIO-NTRK-FUSION",
"value": "positive"
},
{
"finding": "BIO-MSI",
"value": "high"
},
{
"finding": "BIO-BRCA-GERMLINE",
"value": "positive"
}
],
"type": "biomarker"
}
Notes
Intrahepatic cholangiocarcinoma is the most molecularly fertile of GI tumors: FGFR2 fusions (~10–15% iCCA) — pemigatinib (FIGHT-202), futibatinib (FOENIX-CCA2), infigratinib; IDH1 R132 (~15% iCCA) — ivosidenib (ClarIDHy); BRAF V600E (~5%) — dabrafenib + trametinib (ROAR basket); HER2 amp (~5–15% extrahepatic / GBC) — trastuzumab + pertuzumab (MyPathway), zanidatamab (HERIZON-BTC-01); NTRK fusion (<1%) — larotrectinib / entrectinib; MSI-H (~1%) — pembrolizumab (KEYNOTE-158); BRCA — olaparib data emerging. Comprehensive genomic profiling at diagnosis is now standard for advanced biliary cancer (NCCN Cat 1 recommendation level for iCCA). Each positive biomarker re-routes the Algorithm.
Used By
No reverse references found in the YAML corpus.